Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Français (Suisse)
Italiano
Nederlands (Nederland)
Nederlands (België)
MARKETS
Equities
United States
North America
Europe
Asia
Middle East
More Equities
Indexes
S&P 500
DOW JONES
NASDAQ 100
EURO STOXX 50
NIKKEI 225
More Indexes
Currency / Forex
USD / EUR
USD / CAD
USD / MXN
USD / BRL
USD / INR
More Currencies
Commodities
GOLD
CRUDE OIL (WTI)
CRUDE OIL (BRENT)
SILVER
PLATINUM
More Commodities
Cryptocurrencies
BITCOIN
ETHEREUM
Trackers & ETF
Rankings and News
Advanced Search
NEWS
Latest News
Companies
Markets
Economy
Currency / Forex
Commodities
Interest Rates
Finance Pro.
Business Leaders
Cryptocurrencies
Cybersecurity
Economic Calendar
Listed companies
Analyst Reco.
Rumors
IPOs
Capital Markets Transactions
New Contracts
Profit Warnings
Appointments
Press Releases
Events
Security Transactions
Financial Calendar
Sector News
Energy
Basic Materials
Industrials
Consumer Cyclical
Consumer Non-Cyclical
Financials
Healthcare
Technology
Real Estate
Utilities
ANALYSIS
All Analysis
Must Read
Daily Briefing
Weekly market update
Stock Trading Strategies
STOCK PICKS
All Stock Picks
Subscribe
PORTFOLIOS
My Portfolio
Virtual Portfolios
MarketScreener Portfolios
USA Portfolio
European Portfolio
Asian Portfolio
WATCHLISTS
My Watchlists
Watchlists
My previous session
My most visited
Most popular
Investment Style
Undervalued stocks
ESG stocks
Trend-Following Stocks
Growth stocks
Yield stocks
Momentum stocks
Investment Themes
The future of mobility
Cybersecurity
Biotechnology
Robotics
Water
Education
RANKINGS
Top News
Most Read News
Hot News
Top Fundamentals
Top Capitalization
Top Yield
Top PER
Top Consensus
Top Fundamentals
Top ranking ESG
Top Technicals
Top RSI
Unusual volumes
Top Gaps
Top STIM
Breakouts
Trends
Top Movers
Top USA
Top Canada
Top U.K.
Top Germany
Top Europe
Top Asia
SCREENERS
Investment Themes
Ageing Population
Sin stocks
Europe's family businesses
US Basketball
Fintechs
Financial Data
Technical Rankings
Oversold stocks
Overbought stocks
Close to resistance
Close to support
Accumulation Phases
Most volatile stocks
Fundamental Rankings
Top Investor Rating
Top Trading Rating
Top Consensus
Growth stocks
Yield stocks
Low valuations
Stock Screener Home
My Screeners
All my stocks
Watchlists
Virtual Portfolios
TOOLS
MarketScreener tools
Stock Screener
iPhone App
Expert tools
Stock Screener PRO
Portfolio Creator
Event Screener
Tools
Dynamic Chart
Financial Calendar
Economic Calendar
Sector Research
Currency Converter
ProRealTime Trading
OUR SERVICES
MarketScreener Portfolios
European Portfolio
USA Portfolio
Asian Portfolio
Our Stock Picks
Thematic Investment Lists
Stock Screener
Homepage
Equities
Netherlands
Euronext Amsterdam
Galapagos NV
News
Press Releases
GLPG
BE0003818359
GALAPAGOS NV
(GLPG)
Add to my list
Report
Real-time Euronext Amsterdam -
05/25 11:35:02 am EDT
51.26
EUR
-0.58%
05/24
Galapagos In-Licenses Drug Targets for Inflammatory Bowel Disease From Scipher
MT
05/20
Intervest Offices & Warehouses Extends Lease Deals For Office Portfolio In Belgium
MT
05/09
RBC Raises Price Target on Galapagos to $62 From $60, Maintains Sector Perform Rating
MT
Summary
Quotes
Charts
News
Ratings
Calendar
Company
Financials
Consensus
Revisions
Summary
Most relevant
All News
Analyst Reco.
Other languages
Press Releases
Official Publications
Sector news
MarketScreener Strategies
Communiqués de presse de la société GALAPAGOS NV
05/06
Galapagos creates new subscription right plans
GL
05/06
Galapagos creates new subscription right plans
AQ
05/05
Galapagos demonstrates regulatory and commercial progress in Q1 2022
GL
04/27
GALAPAGOS
: announces appointment of Dr. Paul Stoffels as Chairman of the board - Form 6-K
PU
04/26
Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board
GL
04/11
SUBJECT
: Galapagos AGM/EGM 2022 April 11th, 2022 - Form 6-K
PU
04/11
GALAPAGOS
: Chairman letter to shareholders
PU
04/01
GALAPAGOS
: Glpg egm & agm 2022
PU
03/28
Jyseleca® approved in Japan for ulcerative colitis
AQ
03/25
GALAPAGOS
: Proposal of one-tier board structure & appointment of three new directo..
PU
03/24
GALAPAGOS
: Statutory auditor's report on the non-consolidated financial statements per 31..
PU
03/24
CORRECTION
: Galapagos publishes 2021 annual report and announces extraordinary and annual..
GL
03/24
Galapagos publishes 2021 annual report and announces extraordinary and annual sharehold..
AQ
03/24
GALAPAGOS
: increases share capital through subscription right exercises - Form 6-K
PU
03/18
Galapagos increases share capital through subscription right exercises
AQ
02/24
GALAPAGOS
: 2021 results set stage for future growth - Form 6-K
PU
02/24
Galapagos 2021 results set stage for future growth
GL
02/07
GALAPAGOS
: provides further insights into the treatment of ulcerative colitis at the Euro..
PU
02/07
GALAPAGOS
: receives transparency notification from EcoR1 Capital - Form 6-K
PU
02/03
Galapagos receives transparency notification from EcoR1 Capital
AQ
02/02
Galapagos provides further insights into the treatment of ulcerative colitis at the Eur..
AQ
01/27
GALAPAGOS
: appoints Paul Stoffels as Chief Executive Officer - Form 6-K
PU
01/26
GALAPAGOS
: creates new subscription right plan - Form 6-K
PU
01/26
Galapagos creates new subscription right plan
AQ
01/26
Galapagos appoints Paul Stoffels as Chief Executive Officer
AQ
01/19
GALAPAGOS
: JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WIT..
PU
01/18
Jyseleca®▼ (filgotinib) licensed for the treatment of adult patients with moderat..
AQ
01/13
GALAPAGOS
: creates new subscription right plan - Form 6-K
PU
01/13
Galapagos creates new subscription right plan
AQ
01/10
GALAPAGOS
: to present at 40th Annual J.P. Morgan Healthcare Conference - Form 6-K
PU
01/06
Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference
AQ
2021
GALAPAGOS
: increases share capital through subscription right exercises - Form 6-K
PU
2021
Galapagos increases share capital through subscription right exercises
GL
2021
Galapagos increases share capital through subscription right exercises
GL
2021
GALAPAGOS
: completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in poly..
PU
2021
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in pol..
AQ
2021
GALAPAGOS
: Jyseleca®▼(filgotinib) approved in the European Union for the treatment ..
PU
2021
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcera..
GL
2021
Galapagos reports commercial and operational progress at Q3 financial results - Form 6-..
PU
2021
Galapagos reports commercial and operational progress at Q3 financial results
AQ
2021
GALAPAGOS
: presents new data from the SELECTION Phase 3 program at the United European Ga..
PU
2021
GALAPAGOS
: announces completion of patient enrollment for DIVERSITY Phase 3 study with fi..
PU
2021
GALAPAGOS
: presents new data from the SELECTION Phase 3 program at the United European Ga..
AQ
2021
GALAPAGOS
: announces completion of patient enrollment for DIVERSITY Phase 3 study with fi..
AQ
2021
GALAPAGOS
: increases share capital through subscription right exercises (Form 6-K)
PU
2021
GALAPAGOS
: N.V., - Galapagos increases share capital through subscription right exercises
PU
2021
GALAPAGOS
: increases share capital through subscription right exercises
AQ
2021
GALAPAGOS
: ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT O..
PU
2021
GALAPAGOS
: N.v., - galapagos announces positive chmp opinion for jyseleca® (filgotinib) f..
PU
2021
GALAPAGOS
: Announces positive chmp opinion for jyseleca® (filgotinib) for the treatment o..
AQ
2021
GALAPAGOS NV
: - Bionity - Galapagos announces planned retirement of CEO
AQ
2021
GALAPAGOS
: announces planned retirement of CEO (Form 6-K)
PU
2021
GALAPAGOS
: announces planned retirement of CEO
AQ
2021
GALAPAGOS
: reports H1 financial results with refocused pipeline and operational progress
AQ
2021
GALAPAGOS
: N.V., - Galapagos reports positive topline results with selective TYK2 inhibit..
PU
2021
GALAPAGOS
: N.V., - Galapagos demonstrates early clinical activity with SIK2/3 inhibition ..
PU
2021
GALAPAGOS
: demonstrates early clinical activity with SIK2/3 inhibition in inflammation (F..
PU
2021
GALAPAGOS
: reports positive topline results with selective TYK2 inhibitor GLPG3667 in Pha..
PU
2021
GALAPAGOS
: demonstrates early clinical activity with SIK2/3 inhibition in inflammation
AQ
2021
GALAPAGOS
: reports positive topline results with selective TYK2 inhibitor GLPG3667 in Pha..
AQ
2021
GALAPAGOS
: announces new data supporting rapid symptom improvement and sustained steroid-..
AQ
2021
GALAPAGOS
: announces departure of CSO Piet Wigerinck later this year (Form 6-K)
PU
2021
GALAPAGOS
: increases share capital through subscription right exercises (Form 6-K)
PU
2021
Galapagos increases share capital through subscription right exercises
GL
2021
GALAPAGOS
: SELECTION study on filgotinib in ulcerative colitis published in The Lancet (F..
PU
2021
GALAPAGOS
: to present data on rheumatoid arthritis at the upcoming European League Agains..
PU
2021
GALAPAGOS
: announces first patient enrolled in FILOSOPHY study to advance understanding o..
PU
2021
Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding ..
GL
2021
GALAPAGOS
: refocuses pipeline and rightsizes operations (Form 6-K)
PU
2021
GALAPAGOS
: Transparency notification received from The Capital Group
AQ
2021
GALAPAGOS
: creates new subscription right plans
PU
2021
GALAPAGOS
: Written questions and answers
PU
2021
GALAPAGOS
: Extension of lock-up period in Gilead-Galapagos collaboration agreement
AQ
2021
GALAPAGOS NV
: - Publication of the annual report and invitation to the ordinary sharehold..
AQ
2021
GALAPAGOS
: Statutory auditor's report on the non-consolidated financial statements per 31..
PU
1
2
3
4
5
6
7
Next
Official Publications
05/06
Press Release
05/05
1st quarter report
05/05
1st quarter report
04/26
Nomination
03/24
Report
03/24
Report
More Official Publications
Upcoming event on GALAPAGOS NV
06/08/22
Jefferies Healthcare Conference
Company calendar
Upcoming sector events
07/26/22
IQVIA HOLDINGS INC.
: Interim 2022 Earnings Release (Projected)
07/27/22
LONZA GROUP AG
: Interim 2022 Earnings Release (Projected)
07/28/22
SEAGEN INC.
: Interim 2022 Earnings Release (Projected)
08/10/22
MODERNA, INC.
: Interim 2022 Earnings Release (Projected)
More events
Sector
Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research
Slave